Skip to main content

Table 2 Patient-reported outcome (PRO) scores at baseline

From: Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study

PRO

Exenatide BID

Insulin

N = 1114 a

N = 1274 a

IWQOL-Lite*

  

Total score

n = 715

n = 817

 

77.25 (19.41)

84.49 (17.37)

Subscales

n = 648–707b

n = 725–812b

 Physical function

69.35 (23.68)

77.84 (21.03)

 Self-esteem

76.31 (26.68)

86.47 (21.41)

 Sexual life

76.25 (28.50)

82.54 (26.81)

 Public distress

89.25 (18.77)

93.60 (15.51)

 Work

85.50 (20.15)

90.25 (18.09)

EQ-5D

  

 Index score**

n = 1079

n = 1242

 

0.73 (0.27)

0.71 (0.27)

Subscales

n = 1086–1090

n = 1249–1254

Number (%)c of patients who reported at least some problems with:

  

 Mobility

322 (28.9)

442 (34.7)

 Self-care

76 (6.8)

125 (9.8)

 Usual activities

232 (20.8)

301 (23.6)

 Pain/discomfort

588 (52.8)

679 (53.3)

 Anxiety/depression

523 (46.9)

607 (47.6)

VAS score++

n = 1063

n = 1225

 

64.63 (17.94)

63.77 (19.13)

DHP-18***

  

 Barriers to activity

n = 1090

n = 1251

 

30.95 (21.41)

29.45 (19.41)

 Disinhibited eating

n = 1089

n = 1253

 

45.88 (21.75)

38.35 (21.65)

 Psychological distress

n = 1086

n = 1245

 

29.18 (21.34)

26.53 (21.07)

HADS + anxiety

n = 692

n = 794

 

6.38 (4.40)

6.96 (4.59)

HADS + depression

n = 695

n = 787

 

5.44 (4.09)

6.04 (4.35)

  1. Data are presented as mean (SD), unless otherwise stated.
  2. PRO = patient-reported outcome; BID = twice daily, IWQOL-Lite = Impact of Weight on Quality of Life-Lite, EQ-5D = EuroQoL-5D, VAS = visual analogue scale, DHP-18 = Diabetes Health Profile-18, HADS = Hospital Anxiety and Depression Scale.
  3. aN represents the number of patients who attended a baseline visit. Percentages are based on N. The number of patients with data for each endpoint or group of endpoints (n) is presented above that endpoint or group of endpoints.
  4. bFor both cohorts, the lowest n number for the IWQOL-Lite subscales was for data for the sexual life subscale, the highest n number was for the physical function subscale.
  5. cPercentages are based on the number of patients who attended the baseline visit.
  6. *IWQOL-Lite standardised scores, range 0–100. Higher scores indicate higher quality of life. As IWQOL-Lite was not applied in Germany, the numbers of patients who attended a baseline visit and had the opportunity to provide IWQOL-Lite data were 730 (exenatide BID cohort) and 836 (insulin cohort).
  7. **U.K.-specific coefficients and country-specific coefficients were used where available. Higher scores indicate better health status.
  8. ++Range 0–100. Higher scores indicate better health status.
  9. ***Standardised scores for subscales, range 0–100. Lower scores indicate better health-related quality of life.
  10. +Raw scores for subscales, range 0–21. Lower scores indicate lower levels of emotional distress. As HADS Anxiety and Depression were not applied in Germany, the number of patients who attended a baseline visit and had the opportunity to provide HADS data were 730 (exenatide BID cohort) and 836 (insulin cohort).
Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us